18855532

Source:http://linkedlifedata.com/resource/pubmed/id/18855532

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013030, umls-concept:C0036341, umls-concept:C0036751, umls-concept:C0073393, umls-concept:C0087111, umls-concept:C0205419, umls-concept:C0871261, umls-concept:C1332838, umls-concept:C1704632, umls-concept:C1706817, umls-concept:C2698872, umls-concept:C2911692
pubmed:issue	10
pubmed:dateCreated	2008-10-15
pubmed:abstractText	Abnormalities in dopaminergic and serotonergic transmission systems are thought to be involved in the pathophysiology of schizophrenia and the mechanisms underlying the therapeutic effects of antipsychotics. We conducted a pharmacogenetic study to evaluate whether variants in dopamine-related genes (DRD1-DRD5, AKT1 and GSK3beta) and serotonin receptor genes (HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6 and HTR7) can be used to predict the efficacy of risperidone treatment for schizophrenia.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100897350
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Serotonin, http://linkedlifedata.com/resource/pubmed/chemical/Risperidone
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	1744-8042
pubmed:author	pubmed-author:HashimotoShujiS, pubmed-author:IkedaMasashiM, pubmed-author:IwataNakaoN, pubmed-author:KinoshitaYokoY, pubmed-author:KitajimaTsuyoshiT, pubmed-author:NakamuraJunJ, pubmed-author:O'DonovanMichael CMC, pubmed-author:OzakiNorioN, pubmed-author:YamanouchiYoshioY, pubmed-author:YoshimuraReijiR
pubmed:issnType	Electronic
pubmed:volume	9
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1437-43
pubmed:meshHeading	pubmed-meshheading:18855532-Adult, pubmed-meshheading:18855532-Antipsychotic Agents, pubmed-meshheading:18855532-Dopamine, pubmed-meshheading:18855532-Dose-Response Relationship, Drug, pubmed-meshheading:18855532-Female, pubmed-meshheading:18855532-Genetic Variation, pubmed-meshheading:18855532-Genotype, pubmed-meshheading:18855532-Heterozygote, pubmed-meshheading:18855532-Humans, pubmed-meshheading:18855532-Japan, pubmed-meshheading:18855532-Linear Models, pubmed-meshheading:18855532-Male, pubmed-meshheading:18855532-Polymorphism, Single Nucleotide, pubmed-meshheading:18855532-Predictive Value of Tests, pubmed-meshheading:18855532-Psychiatric Status Rating Scales, pubmed-meshheading:18855532-Receptors, Serotonin, pubmed-meshheading:18855532-Risperidone, pubmed-meshheading:18855532-Schizophrenia, pubmed-meshheading:18855532-Time Factors, pubmed-meshheading:18855532-Young Adult
pubmed:year	2008
pubmed:articleTitle	Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.
pubmed:affiliation	Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan. ikeda-ma@fujita-hu.ac.jp
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't